Caswell, Deborah R. http://orcid.org/0000-0002-7550-5092
Gui, Philippe
Mayekar, Manasi K.
Law, Emily K. http://orcid.org/0000-0001-8867-7486
Pich, Oriol http://orcid.org/0000-0002-1956-1882
Bailey, Chris
Boumelha, Jesse http://orcid.org/0000-0001-7635-2537
Kerr, D. Lucas http://orcid.org/0000-0002-0557-8341
Blakely, Collin M. http://orcid.org/0000-0001-8134-3651
Manabe, Tadashi http://orcid.org/0000-0001-9891-5222
Martinez-Ruiz, Carlos
Bakker, Bjorn http://orcid.org/0000-0003-3095-7287
De Dios Palomino Villcas, Juan
I. Vokes, Natalie http://orcid.org/0000-0002-3766-5335
Dietzen, Michelle http://orcid.org/0000-0002-6853-7563
Angelova, Mihaela http://orcid.org/0000-0002-0495-9695
Gini, Beatrice http://orcid.org/0000-0001-6095-1500
Tamaki, Whitney http://orcid.org/0000-0002-1124-628X
Allegakoen, Paul
Wu, Wei http://orcid.org/0000-0002-6556-067X
Humpton, Timothy J. http://orcid.org/0000-0002-8030-9539
Hill, William
Tomaschko, Mona
Lu, Wei-Ting http://orcid.org/0000-0002-1405-4806
Haderk, Franziska
Al Bakir, Maise http://orcid.org/0000-0002-0846-8332
Nagano, Ai http://orcid.org/0000-0002-2354-660X
Gimeno-Valiente, Francisco
de Carné Trécesson, Sophie
Vendramin, Roberto
Barbè, Vittorio
Mugabo, Miriam
Weeden, Clare E.
Rowan, Andrew
McCoach, Caroline E.
Almeida, Bruna
Green, Mary
Gomez, Carlos
Nanjo, Shigeki http://orcid.org/0000-0001-8356-9849
Barbosa, Dora
Moore, Chris
Przewrocka, Joanna
Black, James R. M. http://orcid.org/0000-0001-5598-7752
Grönroos, Eva http://orcid.org/0000-0001-8303-5409
Suarez-Bonnet, Alejandro http://orcid.org/0000-0003-0296-5896
Priestnall, Simon L. http://orcid.org/0000-0002-6027-1879
Zverev, Caroline
Lighterness, Scott
Cormack, James
Olivas, Victor
Cech, Lauren http://orcid.org/0000-0002-3621-4129
Andrews, Trisha
Rule, Brandon http://orcid.org/0000-0002-0757-5363
Jiao, Yuwei
Zhang, Xinzhu
Ashford, Paul http://orcid.org/0000-0003-4079-0257
Durfee, Cameron http://orcid.org/0000-0002-8130-4270
Venkatesan, Subramanian
Temiz, Nuri Alpay http://orcid.org/0000-0003-1416-3639
Tan, Lisa
Larson, Lindsay K.
Argyris, Prokopios P.
Brown, William L. http://orcid.org/0000-0001-5354-9468
Yu, Elizabeth A.
Rotow, Julia K.
Guha, Udayan http://orcid.org/0000-0003-1087-9218
Roper, Nitin
Yu, Johnny
Vogel, Rachel I. http://orcid.org/0000-0003-0149-8464
Thomas, Nicholas J. http://orcid.org/0000-0003-4931-4716
Marra, Antonio
Selenica, Pier
Yu, Helena http://orcid.org/0000-0002-0377-9510
Bakhoum, Samuel F.
Chew, Su Kit
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Jamal-Hanjani, Mariam http://orcid.org/0000-0003-1212-1259
Vousden, Karen H. http://orcid.org/0000-0002-7365-1766
McGranahan, Nicholas
Van Allen, Eliezer M. http://orcid.org/0000-0002-0201-4444
Kanu, Nnennaya
Harris, Reuben S. http://orcid.org/0000-0002-9034-9112
Downward, Julian http://orcid.org/0000-0002-2331-4729
Bivona, Trever G. http://orcid.org/0000-0001-5734-4128
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Article History
Received: 25 June 2023
Accepted: 25 October 2023
First Online: 4 December 2023
Competing interests
: T.G.B. is an advisor to Novartis, AstraZeneca, Revolution Medicines, Array/Pfizer, Springworks, Strategia, Relay, Jazz, Rain, Engine, Granule Therapeutics and EcoR1 and receives research funding from Novartis and Revolution Medicines, Kinnate, Verastem and Strategia. N.I.V. served on an advisory board for Sanofi Genzyme. C.S. acknowledges grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx—collaboration in minimal RD sequencing technologies), Ono Pharmaceutical, and Personalis. He is the chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the Steering Committee Chair. He is also co-chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board (SAB). He receives consultant fees from Achilles Therapeutics (also an SAB member), Bicycle Therapeutics (also an SAB member), Genentech, Medicxi, China Innovation Center of Roche (CICoR) formerly Roche Innovation Center—Shanghai, Metabomed (until July 2022), Relay Therapeutics and the Sarah Cannon Research Institute. C.S. has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana; has previously held stock options in Apogen Biotechnologies and GRAIL; currently has stock options in Epic Bioscience and Bicycle Therapeutics and has stock options and is a cofounder of Achilles Therapeutics. C.S. declares a patent application (PCT/US2017/028013) for methods to lung cancer; targeting neoantigens (PCT/EP2016/059401); identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004); predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912); methods for lung cancer detection (US20190106751A1). He is an inventor on a European patent application (PCT/GB2017/053289) relating to assay technology to detect tumor recurrence. This patent has been licensed to a commercial entity, and under their terms of employment, C.S. is due a revenue share of any revenue generated from such license(s). E.M.V.A. is a consultant for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, Monte Rosa; receives research funding from Novartis, BMS; has equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft and Monte Rosa; has received travel reimbursement from Roche/Genentech and own institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation. C.E.M. is on the advisory board of Genentech; receives honoraria from Novartis, Guardant, Research and receives funding from Novartis, Revolution Medicines. C.M.B. is a consultant for Amgen, Foundation Medicine, Blueprint Medicines and Revolution Medicines; receives research funding from Novartis, AstraZeneca and Takeda and receives institutional research funding from Mirati, Spectrum, MedImmune and Roche. J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics, Saga Diagnostics and Paige.AI, membership of the SAB of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors (BOD) of Grupo Oncoclinicas, and ad hoc SAB of Astrazeneca, Merck, Daiichi Sankyo, Roche Tissue Diagnostics and Personalis, outside the scope of this study. H.Y. receives consulting fees from AstraZeneca, Daiichi, Taiho, Janssen, AbbVie, Blueprint, Black Diamond Research funding to my institution from AstraZeneca, Daiichi, Cullinan, Janssen, Blueprint, Black Diamond, Novartis, Pfizer, ERASCA. S.F.B. owns equity in, receives compensation from, serves as a consultant for and serves on the SAB and BOD of Volastra Therapeutics. He serves on the scientific advisory board of Meliora Therapeutics. M.J.-H. has consulted for, and is a member of, the Achilles Therapeutics Scientific Advisory Board and Steering Committee; has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster and Bristol Myers Squibb and is listed as a co-inventor on a European patent application relating to methods to detect lung cancer (PCT/US2017/028013). This patent has been licensed to commercial entities and, under terms of employment, M.J.-H. is due a share of any revenue generated from such license(s). The other authors have no competing interests to declare.